Ovid Therapeutics has become the latest group to be punished for pushing into pivotal trials after unconvincing phase II data. And the late-stage failure of its Angelman project, OV101, has also exposed the thin pipeline in this rare genetic disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,